prostate specific membrane antigen
Vaccineexperimental
TAH molecule, also known as N-acetyl-L-aspartyl-L-glutamate peptidase I, NAAG peptidase, or prostate-specific membrane antigen (PSMA) is an enzyme that in humans is encoded by the FOLH1 gene. Human GCPII contains 750 amino acids and weighs approximately 84 kDa. — Wikipedia
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2007 (NCT00423254)
Timeline
Indications
Studied for
- Biliary Tract Neoplasms · Phase 1
- Breast Neoplasms · Phase 1
- Carcinoma · Phase 1
- Colorectal Neoplasms · Phase 1
- Endometrial Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 1
- Gallbladder Neoplasms · Phase 1
- Glioblastoma · Phase 2
- Gliosarcoma · Phase 2
- Kidney Diseases · Phase 1
- Liver Neoplasms · Phase 1
- Melanoma · Phase 1
- Mesothelioma · Phase 1
- Neuroendocrine Tumors · Phase 1
- Osteosarcoma · Phase 1
- Ovarian Diseases · Phase 1
- Pancreatic Neoplasms · Phase 1
- Prostate · Phase 1
- Prostatic Neoplasms · Phase 2
- Rectal Neoplasms · Phase 1
- Sarcoma · Phase 1
- Small Cell Lung Carcinoma · Phase 1
- Stomach Neoplasms · Phase 1
- Testicular Neoplasms · Phase 1
- Thyroid Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
- Glutamate carboxypeptidase IIImmunity, active
FOLH1 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGlutamate carboxypeptidase II ↗
Also known as
- prostate specific membrane antigen
- prostate specific membrane antigen
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02020135 | Phase 2 | Oct 1, 2013 | Progenics |
| NCT01856933 | Phase 2 | May 1, 2013 | Brown University, Progenics, Rhode Island Hospital, The University of Texas, Dallas |
| NCT01695044 | Phase 2 | Sep 1, 2012 | Progenics |
| NCT01414296 | Phase 1 | Jan 1, 2009 | Progenics |
| NCT01414283 | Phase 1 | Oct 1, 2008 | Progenics |
| NCT00423254 | Phase 1 | Feb 1, 2007 | MannKind Corp |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Progenics | For profit | 5 | 4 | 2 | 2008 |
| Brown University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| MannKind Corp | For profit | 1 | 1 | 1 | 2007 |
| Rhode Island Hospital | Academic/Hospital | 1 | 0 | 1 | 2013 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 0 | 1 | 2013 |
5 organizations
Page 1 / 1